Clinical Trial Update: Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of partially HLA-mismatched haploidentical allogeneic bone marrow transplantation for hematologic malignancies was terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Hematologic Malignancies | Phase 2 | Status: TERMINATED | Results posted: 2020-02-25